Stevens Capital Management LP acquired a new stake in Anika Therapeutics Inc. (NASDAQ:ANIK) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 3,826 shares of the biotechnology company’s stock, valued at approximately $222,000.

A number of other large investors have also recently modified their holdings of ANIK. Teachers Advisors LLC grew its position in Anika Therapeutics by 0.6% in the first quarter. Teachers Advisors LLC now owns 169,077 shares of the biotechnology company’s stock valued at $7,345,000 after acquiring an additional 1,061 shares in the last quarter. Thrivent Financial For Lutherans grew its position in Anika Therapeutics by 4.0% in the first quarter. Thrivent Financial For Lutherans now owns 8,240 shares of the biotechnology company’s stock valued at $358,000 after acquiring an additional 320 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Anika Therapeutics by 5.5% in the first quarter. Dimensional Fund Advisors LP now owns 771,699 shares of the biotechnology company’s stock valued at $33,522,000 after acquiring an additional 40,020 shares in the last quarter. Morgan Stanley grew its position in Anika Therapeutics by 0.3% in the first quarter. Morgan Stanley now owns 90,103 shares of the biotechnology company’s stock valued at $3,914,000 after acquiring an additional 303 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its position in Anika Therapeutics by 5.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 64,843 shares of the biotechnology company’s stock valued at $2,817,000 after acquiring an additional 3,408 shares in the last quarter. 83.95% of the stock is owned by institutional investors.

Several brokerages have issued reports on ANIK. Barrington Research increased their price objective on shares of Anika Therapeutics from $53.00 to $57.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. BidaskClub raised shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 8th. Finally, Zacks Investment Research raised shares of Anika Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 2nd.

In other news, CEO Charles H. Sherwood sold 3,293 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $60.04, for a total transaction of $197,711.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Charles H. Sherwood sold 22,228 shares of the firm’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $60.06, for a total transaction of $1,335,013.68. Following the sale, the chief executive officer now directly owns 158,297 shares of the company’s stock, valued at approximately $9,507,317.82. The disclosure for this sale can be found here. Insiders have sold 38,636 shares of company stock valued at $2,320,435 in the last three months. Corporate insiders own 6.57% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/11/22/stevens-capital-management-lp-invests-222000-in-anika-therapeutics-inc-anik-stock.html.

Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) opened at $54.77 on Wednesday. Anika Therapeutics Inc. has a 1 year low of $41.64 and a 1 year high of $60.29. The firm has a market cap of $791.30, a P/E ratio of 25.34, a PEG ratio of 2.83 and a beta of 1.47.

Anika Therapeutics (NASDAQ:ANIK) last released its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.05. Anika Therapeutics had a net margin of 28.23% and a return on equity of 13.40%. The business had revenue of $27.18 million during the quarter, compared to the consensus estimate of $27.44 million. During the same quarter last year, the company earned $0.59 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. research analysts anticipate that Anika Therapeutics Inc. will post 1.9 earnings per share for the current fiscal year.

About Anika Therapeutics

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.